Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
2.810
+0.145 (5.44%)
At close: Apr 1, 2025, 4:00 PM
2.670
-0.140 (-4.98%)
After-hours: Apr 1, 2025, 4:38 PM EDT
Company Description
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel.
It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.
Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Scinai Immunotherapeutics Ltd.
| Country | Israel |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Amir Reichman |
Contact Details
Address: Jerusalem BioPark, 2nd floor Jerusalem Israel | |
| Phone | 972 8 930 2529 |
| Website | scinai.com |
Stock Details
| Ticker Symbol | SCNI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611747 |
| CUSIP Number | 09073Q204 |
| ISIN Number | US09073Q2049 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Amir Reichman M.B.A., M.Sc. | Chief Executive Officer and Director |
| Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Dr. Dalit Weinstein Fischer Ph.D. | Chief Technology Officer |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist |
| Merav Kamensky | Head of Quality Control |
| Dr. Naama Adi Hen | Head of Quality Asurance |
| Alona Tal | Head of Business Administration |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 6-K | Report of foreign issuer |
| Mar 26, 2025 | SCHEDULE 13G | Filing |
| Mar 24, 2025 | 6-K | Report of foreign issuer |
| Mar 13, 2025 | 424B3 | Prospectus |
| Mar 12, 2025 | EFFECT | Notice of Effectiveness |
| Mar 11, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Mar 5, 2025 | 6-K | Report of foreign issuer |
| Mar 4, 2025 | SCHEDULE 13G/A | Filing |
| Mar 4, 2025 | F-1 | Registration statement for certain foreign private issuers |
| Mar 4, 2025 | 6-K | Report of foreign issuer |